For more than 30 years, Analysis Group has worked with prominent clinicians, academics, and industry thought leaders to develop innovative solutions for our health care clients across North America, Europe, and emerging markets.

Analysis Group will present one podium presentation and eight poster presentations, detailed below, at the 2017 ICPE conference. Our podium presentation will examine the severe adverse events impact on overall survival and costs for elderly patients with advanced non-small cell lung cancer during second-line therapy. In addition, our research posters will explore the value of transfusion independence in severe aplastic anemia, the overall survival rate of patients with glioblastoma before and after the approval of bevacizumab, health care resources before and after perampanel initiation in the treatment of epilepsy in the U.S., and the association between the duration of somatostatin analogs use and quality of life in patients with carcinoid syndrome in the U.S., among other topics.